26196 1 ap Search Results


glp1r  (Proteintech)
94
Proteintech glp1r
FIGURE 5 | Chronic effects of CLZ on hepatic <t>PGRMC1-EGFR/GLP1R</t> pathway and concentrations of PROG in plasma, liver and adrenal gland. (A) PGRMC1 (B) the ratio of p-EGFR/EGFR (C) GLP1R (D) PROG concentrations (ng/ml) in plasma (H = 12.53, p = 0.0138); (E) PROG concentrations (ng/g) in liver (H = 21.73, p = 0.0002); (F) PROG concentrations (ng/g) in adrenal gland (H = 20.15, p = 0.0005).
Glp1r, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/26196+1+ap/GLP1R+Antibody/10__18314_slash_jnb__v4i2__1081-96-18-28
Average 94 stars, based on 1 article reviews
glp1r - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

Image Search Results


FIGURE 5 | Chronic effects of CLZ on hepatic PGRMC1-EGFR/GLP1R pathway and concentrations of PROG in plasma, liver and adrenal gland. (A) PGRMC1 (B) the ratio of p-EGFR/EGFR (C) GLP1R (D) PROG concentrations (ng/ml) in plasma (H = 12.53, p = 0.0138); (E) PROG concentrations (ng/g) in liver (H = 21.73, p = 0.0002); (F) PROG concentrations (ng/g) in adrenal gland (H = 20.15, p = 0.0005).

Journal: Journal of Nutritional Biology

Article Title: Insulin Receptor Levels Regulated by the Receptor- Associated Protein Progesterone Receptor Membrane Component 1 (PGRMC1)

doi: 10.18314/jnb.v4i2.1081

Figure Lengend Snippet: FIGURE 5 | Chronic effects of CLZ on hepatic PGRMC1-EGFR/GLP1R pathway and concentrations of PROG in plasma, liver and adrenal gland. (A) PGRMC1 (B) the ratio of p-EGFR/EGFR (C) GLP1R (D) PROG concentrations (ng/ml) in plasma (H = 12.53, p = 0.0138); (E) PROG concentrations (ng/g) in liver (H = 21.73, p = 0.0002); (F) PROG concentrations (ng/g) in adrenal gland (H = 20.15, p = 0.0005).

Article Snippet: Approximately 20 mg of protein was loaded, electrophoresed, blotted and then incubated with primary antibodies against PGRMC1, EGFR, GLP1R, PI3K p85, Akt, phospho-Akt (Ser473), GSK-3b, FOXO1, b-actin, PCNA (Proteintech Group, Wuhan, China), phospho-EGFR, phospho-GSK-3b (Affinity) overnight at 4°C.

Techniques: Clinical Proteomics

FIGURE 6 | Illustrative model of the mechanism focusing on hepatic PGRMC1 signaling underlying chronic CLZ-induced hepatic glucose disturbances. The add-on PGRMC1-OE can reverse CLZ-induced hepatic glucose disturbances by upregulating the expression of PGRMC1-EGFR/GLP1R-PI3K-Akt-GSK3b accompanied with the downregulation of nuclear FOXO1. CLZ, CLZ; AG205, the specific inhibitor of PGRMC1; PGRMC1-KD, the knockdown of PGRMC1; PGRMC1-OE, the overexpression of PGRMC1; H&E, hematoxylin and eosin staining; PAS, Periodic acid–Schiff staining; PGRMC1, PROG receptor membrane component 1; EGFR, epidermal growth factor receptor; GLP1R, glucagon-like peptide-1 receptor; PI3K, 3-phosphoinositide-dependent kinase-1; Akt, protein kinase B; GSK3b, glycogen synthase kinase-3b; FOXO1, the fork head box protein 1.

Journal: Journal of Nutritional Biology

Article Title: Insulin Receptor Levels Regulated by the Receptor- Associated Protein Progesterone Receptor Membrane Component 1 (PGRMC1)

doi: 10.18314/jnb.v4i2.1081

Figure Lengend Snippet: FIGURE 6 | Illustrative model of the mechanism focusing on hepatic PGRMC1 signaling underlying chronic CLZ-induced hepatic glucose disturbances. The add-on PGRMC1-OE can reverse CLZ-induced hepatic glucose disturbances by upregulating the expression of PGRMC1-EGFR/GLP1R-PI3K-Akt-GSK3b accompanied with the downregulation of nuclear FOXO1. CLZ, CLZ; AG205, the specific inhibitor of PGRMC1; PGRMC1-KD, the knockdown of PGRMC1; PGRMC1-OE, the overexpression of PGRMC1; H&E, hematoxylin and eosin staining; PAS, Periodic acid–Schiff staining; PGRMC1, PROG receptor membrane component 1; EGFR, epidermal growth factor receptor; GLP1R, glucagon-like peptide-1 receptor; PI3K, 3-phosphoinositide-dependent kinase-1; Akt, protein kinase B; GSK3b, glycogen synthase kinase-3b; FOXO1, the fork head box protein 1.

Article Snippet: Approximately 20 mg of protein was loaded, electrophoresed, blotted and then incubated with primary antibodies against PGRMC1, EGFR, GLP1R, PI3K p85, Akt, phospho-Akt (Ser473), GSK-3b, FOXO1, b-actin, PCNA (Proteintech Group, Wuhan, China), phospho-EGFR, phospho-GSK-3b (Affinity) overnight at 4°C.

Techniques: Expressing, Knockdown, Over Expression, Staining, Membrane